<DOC>
	<DOCNO>NCT01492686</DOCNO>
	<brief_summary>The primary objective study confirm efficacy 60 mg MCI-186 via intravenous drip infusion day patient ALS base change revise ALS functional rating scale ( ALSFRS-R ) score 24 week administration double-blind , placebo-controlled manner . The study also examine safety MCI-186 ALS patient .</brief_summary>
	<brief_title>Phase 3 Study MCI-186 Treatment Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Phenylmethylpyrazolone</mesh_term>
	<mesh_term>Antipyrine</mesh_term>
	<criteria>Patients whose condition define `` definite ALS '' `` probable ALS '' diagnostic criterion revise EL Escorial Airlie House . Patients eat meal , excrete , move oneself alone , need assistance everyday life . Patients le 2 year onset ALS . Patients whose progress condition 12 week administration meet requirement . Patients complication Parkinson 's disease , schizophrenia , dementia , renal failure , severe complication , patient anamnesis hypersensitivity edaravone . Pregnant , lactating , probably pregnant patient , patient want become pregnant , patient agree contraception . Patients participate trial within 12 week consent , participate clinical trial present . In addition exclusion criterion , patient judge inadequate participate study physician .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis ( ALS )</keyword>
</DOC>